Nimble leaves Roche to commercialize chemical synthesis technology

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Caiaimage/MartinBarraud)
(Image: Getty/Caiaimage/MartinBarraud)

Related tags Roche Chemical synthesis Technology Commercialization Drug discovery Drug development Drug development process

Nimble Therapeutics spun out from parent company Roche to commercialize its chemical synthesis technology for drug discovery and development.

Nimble will operate as an independent business after Roche spun out the company and will look to establish strategic partnerships to jointly develop ‘unique’ drug candidates across various therapeutic areas, according to CEO, Jigar Patel.

Roche acquired Nimble​, then NimbleGen, in a $272.5m (€203m) deal in 2007. The Roche team that helped develop the chemical synthesis technology will join the fully independent company.

Board director at Nimble, Deval Lashkari, said in a statement, “The Roche team saw the value in separating the business to enable it to expand its platform and work on a variety of therapeutic areas with strategic partners.”

According to Nimble, the chemical synthesis technology platform can synthesize ‘millions’ of unique natural and modified peptide-based molecules.

Based in Madison, Wisconsin, Nimble has also developed biological assays that can be used for empirical optimization of molecules.

Related news

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us


View more